GlassScriptPhysician profile
Carl Goldsand
NPI 1447245212
$7,393.70
in general payments reported to CMS, 2019-2025
22 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $88.91 · 2021: $509 · 2022: $1,505 · 2023: $2,345 · 2024: $1,742 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Education: $54.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.36 |
| Education | $54.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,120.78 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $1,045.74 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $1,017.56 | 2022-2025 | |
| Vifor Pharma, INC. | $721.58 | 2019-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $563.74 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $520.09 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $340.15 | 2023-2025 | Purified Cortrophin Gel |
| Amgen INC. | $330.42 | 2019-2024 | Tavneos, Krystexxa, Aranesp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.35 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $262.00 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $242.15 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $196.65 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $189.57 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $184.99 | 2022-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $91.17 | 2023-2025 | Ozempic, Rybelsus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $88.27 | 2022-2023 | Benlysta |
| Ardelyx, INC. | $67.57 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $61.03 | 2019 | |
| Akebia Therapeutics INC | $24.24 | 2024 | Vafseo, Auryxia |
| Shire North American Group INC | $20.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.53 | 2023 | |
| Opko Pharmaceuticals, LLC | $19.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Goldsand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.